Market Research Logo

Nasopharyngeal Cancer - Pipeline Review, H1 2015

Nasopharyngeal Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Nasopharyngeal Cancer - Pipeline Review, H1 2015’, provides an overview of the Nasopharyngeal Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nasopharyngeal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngeal Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Nasopharyngeal Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Nasopharyngeal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Nasopharyngeal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Nasopharyngeal Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Nasopharyngeal Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Nasopharyngeal Cancer Overview
Therapeutics Development
Pipeline Products for Nasopharyngeal Cancer – Overview
Pipeline Products for Nasopharyngeal Cancer – Comparative Analysis
Nasopharyngeal Cancer – Therapeutics under Development by Companies
Nasopharyngeal Cancer – Therapeutics under Investigation by Universities/Institutes
Nasopharyngeal Cancer – Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Nasopharyngeal Cancer – Products under Development by Companies
Nasopharyngeal Cancer – Products under Investigation by Universities/Institutes
Nasopharyngeal Cancer – Companies Involved in Therapeutics Development
Ambrx, Inc.
AVEO Pharmaceuticals, Inc.
BioDiem Ltd
Celgene Corporation
Cyclacel Pharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Merck & Co., Inc.
Otsuka Holdings Co., Ltd.
Pharmacyclics, Inc.
Theravectys S.A.
Zhejiang BetaPharma Co., Ltd.
Nasopharyngeal Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abexinostat hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
azacitidine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy 2 for Oncology and Infectious Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Metastatic Nasopharyngeal Carcinoma and Colorectal Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Nasopharingeal Carcinoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target Latent Membrane Protein-2 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target LMP-1 and LMP-2 for Metastatic Nasopharyngeal Carcinoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target LMP-1 and LMP-2 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cells + Cytokine Induced Killer Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EBV-nRNA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ficlatuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate p53 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2849330 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
icotinib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-2206 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody Drug Conjugate to Inhibit CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NEO-212 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OPB-51602 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RO-5203280 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
seliciclib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Nasopharyngeal and Colon Cancers - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for EBV Associated Nasopharyngeal Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Epstein-Barr Viral Infections and Nasopharyngeal Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine to Target EBV for Nasopharyngeal Carcinoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nasopharyngeal Cancer – Recent Pipeline Updates
Nasopharyngeal Cancer - Dormant Projects
Nasopharyngeal Cancer – Product Development Milestones
Featured News & Press Releases
Dec 16, 2011: Radiation Therapy Oncology Group Trial Results Show Bevacizumab Reduces Spread Of Nasopharyngeal Cancer
May 29, 2009: Cyclacel Reports Initial Phase 2 Seliciclib Data In Patients With Nasopharyngeal Carcinoma At 2009 Asco Annual Meeting
Apr 21, 2009: Cyclacel & Dartmouth Researchers Reports Novel Mechanism Of Action For Seliciclib At AACR
Mar 05, 2009: Cyclacel Announces Phase 1 Data Elucidating Pharmacodynamics & Mechanism Of Action Of Seliciclib In Nasopharyngeal Cancer
Aug 28, 2008: CYCLACEL Announces Recommendations Of Data Review Committee For Seliciclib Phase 2b Non-Small Cell Lung Cancer APPRAISE Trial
Jun 28, 2007: Cyclacel Pharmaceuticals Announces Results Of Phase II Seliciclib Combination Studies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Nasopharyngeal Cancer, H1 2015
Number of Products under Development for Nasopharyngeal Cancer – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Nasopharyngeal Cancer – Pipeline by Ambrx, Inc., H1 2015
Nasopharyngeal Cancer – Pipeline by AVEO Pharmaceuticals, Inc., H1 2015
Nasopharyngeal Cancer – Pipeline by BioDiem Ltd, H1 2015
Nasopharyngeal Cancer – Pipeline by Celgene Corporation, H1 2015
Nasopharyngeal Cancer – Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015
Nasopharyngeal Cancer – Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Nasopharyngeal Cancer – Pipeline by GlaxoSmithKline plc, H1 2015
Nasopharyngeal Cancer – Pipeline by Merck & Co., Inc., H1 2015
Nasopharyngeal Cancer – Pipeline by Otsuka Holdings Co., Ltd., H1 2015
Nasopharyngeal Cancer – Pipeline by Pharmacyclics, Inc., H1 2015
Nasopharyngeal Cancer – Pipeline by Theravectys S.A., H1 2015
Nasopharyngeal Cancer – Pipeline by Zhejiang BetaPharma Co., Ltd., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Nasopharyngeal Cancer Therapeutics – Recent Pipeline Updates, H1 2015
Nasopharyngeal Cancer – Dormant Projects, H1 2015
List of Figures
Number of Products under Development for Nasopharyngeal Cancer, H1 2015
Number of Products under Development for Nasopharyngeal Cancer – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report